Edgewise Therapeutics, Inc. (EWTX)

NASDAQ: EWTX · Real-Time Price · USD

30.15

+0.07 (0.23%)

At close: Feb 18, 2026, 4:00 PM EST

29.57

-0.58 (-1.92%)

After-hours: Feb 18, 2026, 4:29 PM EST

Edgewise Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Selling, General & Admin	36.8	31.87	23.45	17.63	11.03	2.21
Research & Development	144.17	126.97	90.91	54.03	32.19	14.98
Operating Expenses	180.97	158.83	114.36	71.66	43.22	17.19
Operating Income	-180.97	-158.83	-114.36	-71.66	-43.22	-17.19
Interest & Investment Income	23.73	25.02	14.19	4.02	0.4	0.07
Pretax Income	-157.24	-133.81	-100.16	-67.64	-42.81	-17.12
Net Income	-157.24	-133.81	-100.16	-67.64	-42.81	-17.12
Net Income to Common	-157.24	-133.81	-100.16	-67.64	-42.81	-17.12
Shares Outstanding (Basic)	100	92	64	54	38	1
Shares Outstanding (Diluted)	100	92	64	54	38	1
Shares Change (YoY)	17.87%	45.02%	18.90%	42.82%	4977.96%	95.63%
EPS (Basic)	-1.57	-1.45	-1.57	-1.26	-1.14	-23.17
EPS (Diluted)	-1.57	-1.45	-1.57	-1.26	-1.14	-23.17
Free Cash Flow	-132.64	-110.34	-97.69	-58.18	-34.18	-14.84
Free Cash Flow Per Share	-1.32	-1.19	-1.53	-1.09	-0.91	-20.08
EBITDA	-178.83	-156.76	-112.81	-71.29	-42.94	-17.01
D&A For EBITDA	2.14	2.07	1.55	0.37	0.27	0.19
EBIT	-180.97	-158.83	-114.36	-71.66	-43.22	-17.19

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q